{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T03:34:04Z","timestamp":1784086444431,"version":"3.55.0"},"reference-count":35,"publisher":"European Respiratory Society (ERS)","issue":"5","license":[{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2023,6,21]]},"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Severe asthma limits exercise to avoid respiratory symptoms. The objective of the present study was to investigate the role of the 6-min walk test (6MWT) in severe asthma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Consecutive patients with severe eosinophilic asthma were enrolled. A 6MWT was performed before and after 12\u2005months. Inhaled therapy dose, oral corticosteroids dose, pulmonary function tests, eosinophil blood count, fractional exhaled nitric oxide (<jats:italic>F<\/jats:italic><jats:sub>eNO<\/jats:sub>), Asthma Control Test (ACT) score and responses to the Asthma Quality of Life Questionnaire (AQLQ) were also recorded.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of the 22 patients enrolled, 13 were treated with mepolizumab 100\u2005mg every 4\u2005weeks in addition to conventional therapy and nine with conventional therapy only. The majority of the patients were treated with high-dose inhaled corticosteroids\/long-acting \u03b2-agonists\/long-acting muscarinic receptor antagonists, while approximately half were on continuous oral corticosteroids. After 12\u2005months, the mepolizumab group only showed a significant improvement in pulmonary function tests (percentage forced expiratory volume in 1\u2005s and percentage forced expiratory flow at 25\u201375% forced vital capacity (FEF<jats:sub>25\u201375%<\/jats:sub>), both p&lt;0.001; percentage forced vital capacity, p&lt;0.01) and clinical laboratory parameters (eosinophil count,<jats:italic>F<\/jats:italic><jats:sub>eNO<\/jats:sub>measured at a flow rate of 50\u2005mL\u00b7s<jats:sup>\u22121<\/jats:sup>, ACT and AQLQ, p&lt;0.001). No significant changes in the proportion of patients using continuous oral corticosteroids and high-dose inhaled corticosteroids\/long-acting \u03b2-agonists\/long-acting muscarinic receptor antagonists were observed in either group (p&gt;0.05). By paired comparisons, statistically significant improvements of the mean 6-min walk distance (6MWD) were observed in the mepolizumab (p&lt;0.001) and conventional therapy (p&lt;0.01) groups, while no improvement was seen in dyspnoea Borg scale, heart rate, percentage oxygen saturation or systolic and diastolic blood pressure. 6MWD showed significant direct correlations with ACT (r=0.5998, p&lt;0.001), AQLQ (r=0.3978, p=0.009) and FEF<jats:sub>25\u201375%<\/jats:sub>(r=0.3589, p=0.017).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The 6MWT could complement severe asthma assessment and be relevant in evaluating the objective response to treatment, including biological therapies like mepolizumab.<\/jats:p><\/jats:sec>","DOI":"10.1183\/23120541.00114-2023","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T14:51:27Z","timestamp":1688655087000},"page":"00114-2023","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Using the 6-min walk test to assess the clinical response to mepolizumab and conventional therapy in severe eosinophilic asthma"],"prefix":"10.1183","volume":"9","author":[{"given":"Carlo","family":"Lombardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7831-921X","authenticated-orcid":false,"given":"Alvise","family":"Berti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Cottini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"key":"2024101712021331000_9.5.00114-2023.1","first-page":"783","article-title":"The six-minute walk test","volume":"48","author":"Enright","year":"2003","journal-title":"Respir Care"},{"key":"2024101712021331000_9.5.00114-2023.2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.123.2.387"},{"key":"2024101712021331000_9.5.00114-2023.3","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/25.1.12"},{"key":"2024101712021331000_9.5.00114-2023.4","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.166.1.at1102"},{"key":"2024101712021331000_9.5.00114-2023.5","first-page":"273","article-title":"Quality of life in patients with advanced heart failure","volume":"11","author":"Dracup","year":"1992","journal-title":"J Heart Lung Transplant"},{"key":"2024101712021331000_9.5.00114-2023.6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/MCP.0b013e328273bc2b","article-title":"Six-minute walk test in managing and monitoring sarcoidosis patients","volume":"13","author":"Baughman","year":"2007","journal-title":"Curr Opin Pulm Med"},{"key":"2024101712021331000_9.5.00114-2023.7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200604-520OC"},{"key":"2024101712021331000_9.5.00114-2023.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1843.2010.01877.x"},{"key":"2024101712021331000_9.5.00114-2023.9","first-page":"166","article-title":"Prognostic value of 6-minute walk test in stable outpatients with heart failure","volume":"34","author":"Arslan","year":"2007","journal-title":"Tex Heart Inst J"},{"key":"2024101712021331000_9.5.00114-2023.10","doi-asserted-by":"publisher","DOI":"10.1002\/oby.20046"},{"key":"2024101712021331000_9.5.00114-2023.11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1155\/2015\/280187","article-title":"Six-minute walk distance is a predictor of survival in patients with chronic obstructive pulmonary disease undergoing pulmonary rehabilitation","volume":"22","author":"Dajczman","year":"2015","journal-title":"Can Respir J"},{"key":"2024101712021331000_9.5.00114-2023.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.apmr.2009.10.017"},{"key":"2024101712021331000_9.5.00114-2023.13","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2024101712021331000_9.5.00114-2023.14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00634-2017"},{"key":"2024101712021331000_9.5.00114-2023.15","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40413-017-0159-y","article-title":"Severe asthma and quality of life","volume":"10","author":"Hossny","year":"2017","journal-title":"World Allergy Organ J"},{"key":"2024101712021331000_9.5.00114-2023.16","unstructured":"Global Initiative for Asthma (GINA) . Global Strategy for Asthma Management and Prevention. 2016. Available from: http:\/\/ginasthma.org\/"},{"key":"2024101712021331000_9.5.00114-2023.17","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00150314"},{"key":"2024101712021331000_9.5.00114-2023.18","doi-asserted-by":"publisher","DOI":"10.1249\/00005768-198205000-00012"},{"key":"2024101712021331000_9.5.00114-2023.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.10.038"},{"key":"2024101712021331000_9.5.00114-2023.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2010.04.006"},{"key":"2024101712021331000_9.5.00114-2023.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2010.05.009"},{"key":"2024101712021331000_9.5.00114-2023.22","doi-asserted-by":"publisher","DOI":"10.1080\/02770900500498584"},{"key":"2024101712021331000_9.5.00114-2023.23","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01500-2018"},{"key":"2024101712021331000_9.5.00114-2023.24","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2016.03.016"},{"key":"2024101712021331000_9.5.00114-2023.25","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01827-2016"},{"key":"2024101712021331000_9.5.00114-2023.26","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00143-2017"},{"key":"2024101712021331000_9.5.00114-2023.27","doi-asserted-by":"crossref","first-page":"3359","DOI":"10.1016\/j.jaip.2021.04.035","article-title":"Small airway dysfunction links asthma severity with physical activity and symptom control","volume":"9","author":"Abdo","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024101712021331000_9.5.00114-2023.28","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jaip.2019.10.040","article-title":"Clinical characterization and predictors of IOS-defined small-airway dysfunction in asthma","volume":"8","author":"Cottini","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024101712021331000_9.5.00114-2023.29","doi-asserted-by":"crossref","first-page":"106243","DOI":"10.1016\/j.rmed.2020.106243","article-title":"Prevalence and features of IOS-defined small airway disease across asthma severities","volume":"176","author":"Cottini","year":"2021","journal-title":"Respir Med"},{"key":"2024101712021331000_9.5.00114-2023.30","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.crimmu.2022.03.002","article-title":"The emerging roles of eosinophils: implications for the targeted treatment of eosinophilic-associated inflammatory conditions","volume":"3","author":"Lombardi","year":"2022","journal-title":"Curr Res Immunol"},{"key":"2024101712021331000_9.5.00114-2023.31","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.3389\/fphar.2019.01630","article-title":"Physical activity as a new tool to evaluate the response to omalizumab and mepolizumab in severe asthmatic patients: a pilot study","volume":"10","author":"Carpagnano","year":"2019","journal-title":"Front Pharmacol"},{"key":"2024101712021331000_9.5.00114-2023.32","doi-asserted-by":"publisher","DOI":"10.1378\/chest.116.5.1208"},{"key":"2024101712021331000_9.5.00114-2023.33","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.jaip.2017.09.022","article-title":"Physical activity and exercise capacity in severe asthma: key clinical associations","volume":"6","author":"Cordova-Rivera","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2024101712021331000_9.5.00114-2023.34","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00.16586600"},{"key":"2024101712021331000_9.5.00114-2023.35","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/resp.14323","article-title":"Factors associated with 6-min walk distance in severe asthma: a cross-sectional study","volume":"27","author":"Pitzner-Fabricius","year":"2022","journal-title":"Respirology"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00114-2023","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T05:29:14Z","timestamp":1740374954000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00114-2023"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":35,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,10,2]]},"published-print":{"date-parts":[[2023,9]]}},"alternative-id":["10.1183\/23120541.00114-2023"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00114-2023","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,6]]}}}